Metoprolol Succinate 200 mg Tablet, Extended Release, 100-count
by Nivagen Pharmaceuticals, Inc · 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (75834-293-01)
NDC 75834-0293-01
🏷️ FDA NDC (as labeled)
75834-293-01
billing pads the product segment with a zero
This package
Also priced by: Medicaid pays $0.3509/unit · Part D plans $0.2385/unit — full pricing hub ↓
Discontinued
Non-controlled
⚠ Discontinued by firm
🗂️ Data synced Sep 3, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Other active recalls for Metoprolol Succinate (different manufacturers) — 5 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jan 29, 2026 — Failed Dissolution Specifications (Teva Pharmaceuticals USA, Inc) · FDA recall D-0355-2026
Class II · Jan 29, 2026 — Failed Dissolution Specifications (Teva Pharmaceuticals USA, Inc) · FDA recall D-0354-2026
Class II · Jan 29, 2026 — Failed Dissolution Specifications (Teva Pharmaceuticals USA, Inc) · FDA recall D-0357-2026
Class II · Jan 29, 2026 — Failed Dissolution Specifications (Teva Pharmaceuticals USA, Inc) · FDA recall D-0356-2026
Class II · Jun 24, 2025 — Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term. (Granules Pharmaceuticals Inc.) · FDA recall D-0510-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
⚠️
Excluded from the active FDA NDC Directory.
The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Oct 2025. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory.
Search the FDA NDC Directory ↗
🆔 Identity & classification
FDA NDC (as labeled)
75834-293-01
Product NDC
75834-293
11-digit billing NDC
75834029301
NCPDP billing unit
EA — each (per item)
SPL Set ID
d3dfea3b-ad55-c73d-e053-2995a90a72ff
DEA schedule
Non-controlled
Marketing category
DRUG FOR FURTHER PROCESSING
Marketing status
Discontinued
FDA listing status
Discontinued by firm (certified through Oct 2025)
Marketing start
2020-12-01
Dosage form
TABLET, EXTENDED RELEASE
Substance
METOPROLOL SUCCINATE
GPI-14
33200030057540
GPI class
Metoprolol Succinate ER
GCN Seq No
016601
GCN
20743
HICL code
006323
Ingredient (HICL)
Metoprolol Succinate
HIC1 code
J
Therapeutic class — broad (HIC1)
Autonomic Nervous System
HIC2 code
J7
Therapeutic class — intermediate (HIC2)
Antiadrenergics
HIC3 code
J7C
Therapeutic class — specific (HIC3)
Beta-Adrenergic Blocking Agents
AHFS code
12:16.08.08
AHFS class
Selective Beta-Adrenergic Blocking Agent
FDB label name
METOPROLOL SUCC ER 200 MG TAB
FDB brand name
Metoprolol Succinate
Legend status
F — Federal legend — prescription drug or device
Why two NDCs?
The FDA registers this code as 75834-293-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 75834-0293-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
🏭 Manufacturer & labeler
LabelerNivagen Pharmaceuticals, Inc
Labeler code75834
First marketedDec 2020
Product typeDrug For Further Processing
Portfolio4 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
🩺 Clinical
Label name METOPROLOL SUCC ER 200 MG TAB Ingredient Metoprolol Succinate
📖 What it is MedlinePlus · NLM
Metoprolol is used to treat high blood pressure, angina (chest pain) and heart failure. Metoprolol also is used to improve survival after a heart attack . Metoprolol is in a class of medications called beta blockers. It works by relaxing blood vessels and slowing heart rate to improve blood flow and decrease blood pressure.
Read the full MedlinePlus article ↗📗 Our plain-language guide HelloPharmacist
- That depends on why you were prescribed it. Metoprolol is a beta-blocker, which means it slows your heart rate and reduces the workload on your heart. Depending on your formulation...
- What exactly is metoprolol supposed to do for me?
- Please don't stop suddenly — this is one of the most important things to know about this drug. Stopping metoprolol abruptly, especially if you have any heart disease, can cause you...
- Can I stop taking metoprolol if I feel fine or if it makes me tired?
Patient education
Supplement & herbal interactions
1
Nutrient depletion considerations
Metoprolol may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
💬 Questions about Metoprolol Succinate?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.186 | $18.59 / 100 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.3509 | $35.09 / 100 tablets |
| Medicare drug plans payPart D · Q2 2026 | $0.2385 | $23.85 / 100 tablets |
NADAC price history (per ea) — tap or hover for the price & month
▼ Down 31% over the last 17 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Metoprolol succinate 200 mg 70436-0167-01 | Slate | 100 tablets | $0.173 | AB | Availability likely | save 7% |
| Metoprolol Succinate 200 mg 68001-0360-00 | BluePoint | 100 tablets | $0.182 | AB | FDA listed | save 2% |
| Metoprolol Succinate 200 mgthis 75834-0293-01 | Nivagen | 100 tablets | $0.186 | — | Discontinued | — |
| Metoprolol Succinate 200 mg 27808-0305-01 | Cranbury | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol Succinate 200 mg 31722-0592-01 | Camber | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol succinate 200 mg 42806-0727-01 | Epic | 100 tablets | $0.187 | AB | Availability likely | +1% |
| metoprolol succinate 200 mg 45963-0678-11 | Actavis | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol succinate 200 mg 50268-0543-15 | AvPAK | 1 tablet | $0.187 | AB | Availability likely | +1% |
| Metoprolol Succinate 200 mg 50742-0618-01 | Ingenus | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol succinate 200 mg 55111-0469-01 | Dr. | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol Succinate 200 mg 67877-0593-01 | Ascend | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol Succinate 200 mg 68001-0471-00 | BluePoint | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol Succinate 200 mg 68001-0503-00 | BluePoint | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol Succinate 200 mg 68001-0687-00 | BluePoint | 100 tablets | $0.187 | AB | Availability likely | +1% |
| metoprolol succinate 200 mg 68382-0567-01 | Zydus | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol Succinate 200 mg 70010-0783-01 | Granules | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol succinate 200 mg 72516-0028-01 | Oryza | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol Succinate 200 mg 72516-0033-01 | Oryza | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol succinate 200 mg 72603-0145-01 | Northstar | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol succinate 200 mg 75907-0346-01 | Dr. | 100 tablets | $0.187 | AB | Availability likely | +1% |
| Metoprolol succinate 200 mg 82009-0116-05 | Quallent | 500 tablets | $0.187 | AB | Availability likely | +1% |
| Toprol Xl 200 mg 70842-0113-02 | Melinta | 100 tablets | $3.321 | AB | Availability likely | +1686% |
| Metoprolol Succinate 200 mg 51407-0406-01 | Golden | 100 tablets | — | AB | FDA listed | — |
| Metoprolol Succinate 200 mg 62207-0132-49 | Granules | 1000 tablets | — | — | FDA listed | — |
| metoprolol succinate 200 mg 63629-3286-01 | Bryant | 30 tablets | — | AB | FDA listed | — |
| Metoprolol Succinate 200 mg 63629-8866-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Metoprolol Succinate 200 mg 63629-9173-01 | Bryant | 500 tablets | — | AB | FDA listed | — |
| metoprolol succinate 200 mg 63629-9413-01 | Bryant | 30 tablets | — | AB | FDA listed | — |
| Metoprolol succinate 200 mg 68001-0120-00 | BluePoint | 100 tablets | — | AB | FDA listed | — |
| Metoprolol Succinate 200 mg 69097-0409-02 | Cipla | 30 tablets | — | AB | FDA listed | — |
| metoprolol succinate 200 mg 70771-1341-00 | Zydus | 1000 tablets | — | AB | FDA listed | — |
| Metoprolol Succinate 200 mg 71335-2811-01 | Bryant | 30 tablets | — | AB | FDA listed | — |
| Metoprolol succinate 200 mg 71335-3069-01 | Bryant | 30 tablets | — | AB | FDA listed | — |
| Metoprolol succinate 200 mg 71335-3134-01 | Bryant | 30 tablets | — | AB | FDA listed | — |
| Metoprolol Succinate 200 mg 71610-0573-45 | Aphena | 45 tablets | — | AB | FDA listed | — |
| Metoprolol succinate 200 mg 71765-0008-01 | Zhejiang | 100 tablets | — | AB | FDA listed | — |
| Metoprolol Succinate 200 mg 72162-1859-00 | Bryant | 1000 tablets | — | AB | FDA listed | — |
| Metoprolol Succinate 200 mg 60050-0004-99 | Pharmadax | 49000 tablets | — | — | FDA listed | — |
| Metoprolol succinate 200 mg 17228-0111-01 | AstraZeneca | 11000 tablets | — | — | FDA listed | — |
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
⏳ Availability & generic status
🏛️
2020
On the market since
Dec 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
🗺️ Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 75834-0293-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
385
Units reimbursed last 4 qtrs
15.8K
Gross reimbursed last 4 qtrs
$5.5K
Avg / prescription
$14.37
Avg / unit
$0.3509
Latest quarter Q1 2026
38Rx
Medicaid pays / ea
$0.3509
gross reimbursed
vs
NADAC / ea
$0.1859
acquisition cost
=
Spread
+$0.1650
+89% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
Fee-for-service · 185 Rx Managed care · 200 Rx
State Medicaid map
Units reimbursed · per 100k residents
1.640.2
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
💊 Medicaid utilization by pack size
Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
Drug total (last 4 qtrs): 439 Rx · 19,222 units · $6,502 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
Medicare Part D (outpatient prescription) spending for Metoprolol Succinate (matched by generic name) — the program that covers self-administered drugs. 23 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Metoprolol Succinate. CMS lists 3 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$119.69M
Claims incl. refills
8.6M
Beneficiaries
6.5M
Spend / beneficiary
$18.38
Spend / claim
$13.98
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
📦 Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Status |
|---|---|---|---|---|---|
| 75834-0293-00 | 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (75834-293-00) | $0.1668 / ea | $166.83 | 2022-02-23 | Discontinued by firm |
| 75834-0293-01 You're viewing this | 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (75834-293-01) | $0.1859 / ea | $18.59 | 2022-02-23 | Discontinued by firm |
| 75834-0293-05 | 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (75834-293-05) | $0.1668 / ea | $83.42 | 2022-02-23 | Discontinued by firm |
| 75834-0293-99 | 49000 TABLET, EXTENDED RELEASE in 1 DRUM (75834-293-99) | — | — | — | Active |
You're viewing the smallest of 4 pack sizes for this product.
Per ea, this pack runs about 11% above the cheapest pack (1000-count, $0.1668 vs $0.1859 NADAC).
In Medicaid, this is the most-dispensed pack of this product — about 88% of fills over the last four reported quarters. See all packs ↓
Pack size FAQ
What quantity is in NDC 75834-0293-01?
NDC 75834-0293-01 is a 100-count package — 100 tablet, extended release in 1 bottle.
What is the difference between NDC 75834-0293-01 and NDC 75834-0293-05?
Both are Metoprolol Succinate 200 mg Tablet, Extended Release — the drug itself is identical. NDC 75834-0293-01 is the 100-count package, while NDC 75834-0293-05 is the 500 tablets package. Per-ea NADAC also differs: $0.1859 here vs $0.1668 for the 500 tablets pack.
What NDC number is used to bill for this package of Metoprolol Succinate 200 mg Tablet, Extended Release?
Bill NDC 75834-0293-01 — the 11-digit billing format is 75834029301. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
🧭 About this NDC listing & data coverage
Listed for further processing / repackaging
No longer marketed (per FDA listing data)
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Nivagen Pharmaceuticals, Inc supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | ✓ Available |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | ✓ Available |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 75834-293-01, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 75834-0293-01, written without dashes as 75834029301. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 75834-0293-01, the first segment (75834) is the labeler code FDA assigned to Nivagen Pharmaceuticals, Inc; the middle segment (0293) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (01) identifies this exact package size and type. Together they name one specific package of one specific product.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 500 tablets (75834-0293-05), 1000 tablets (75834-0293-00), 49000 tablets (75834-0293-99). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Nivagen Pharmaceuticals, Inc is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
📄 Full FDA label FDA SPL
The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.